ORAMORPH SR Drug Patent Profile

Which patents cover Oramorph Sr, and what generic alternatives are available?

Oramorph Sr is a drug marketed by Xanodyne Pharms Inc and is included in one NDA.

The generic ingredient in ORAMORPH SR is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oramorph Sr

A generic version of ORAMORPH SR was approved as morphine sulfate by HOSPIRA on September 30^th, 1992.

Summary for ORAMORPH SR

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ORAMORPH SR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xanodyne Pharms Inc	ORAMORPH SR	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019977-004	Nov 23, 1994		DISCN	No	No
Xanodyne Pharms Inc	ORAMORPH SR	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019977-003	Aug 15, 1991		DISCN	No	No
Xanodyne Pharms Inc	ORAMORPH SR	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019977-001	Aug 15, 1991		DISCN	No	No
Xanodyne Pharms Inc	ORAMORPH SR	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019977-002	Aug 15, 1991		DISCN	No	No

ORAMORPH SR: Investment & Fundamentals Analysis

Last updated: February 19, 2026

Executive Summary

This analysis examines Oramorph SR, a sustained-release oral formulation of morphine sulfate, for investment and R&D considerations. The drug, marketed by Sandoz, targets moderate to severe pain management. Key factors influencing its market position include patent expiry, generic competition, regulatory landscape, and clinical efficacy. Oramorph SR's market penetration is tied to the established use of morphine in pain treatment and the demand for controlled-release formulations. Competitive pressures from other opioid analgesics and non-opioid alternatives, coupled with evolving pain management guidelines and the opioid crisis, present significant market dynamics.

Market Landscape and Competitive Positioning

What is the current market for sustained-release opioid analgesics?

The market for sustained-release opioid analgesics is mature, with established players and significant generic penetration. These formulations are primarily prescribed for chronic pain conditions, including cancer pain and severe non-cancer pain. The market size is influenced by the prevalence of chronic pain, demographic trends (aging populations), and physician prescribing habits.

Key market characteristics include:

• Dominance of Generic Products: Most branded sustained-release opioid analgesics have experienced patent expiries, leading to a highly competitive generic market. This drives down prices and emphasizes cost-effectiveness for purchasers.
• Therapeutic Equivalence Focus: Prescribers and payers often focus on demonstrating therapeutic equivalence between generic and branded products. Bioequivalence studies are critical for regulatory approval and market acceptance of generics.
• Regulatory Scrutiny: The opioid class of drugs faces intense regulatory oversight due to the potential for misuse, abuse, and diversion. This impacts manufacturing, distribution, prescribing, and marketing practices.
• Shift Towards Non-Opioid Alternatives: Increasing awareness of the risks associated with long-term opioid use is driving a gradual shift towards non-opioid analgesics and multimodal pain management strategies. This trend exerts downward pressure on the overall opioid market share for chronic non-cancer pain.

How does Oramorph SR differentiate itself?

Oramorph SR's primary differentiation stems from its formulation as a sustained-release oral morphine sulfate. This formulation aims to provide consistent pain relief over extended periods, reducing the frequency of dosing compared to immediate-release formulations.

Key differentiators and competitive advantages:

• Morphine Sulfate as the Active Pharmaceutical Ingredient (API): Morphine is a well-established, potent opioid analgesic with a long history of clinical use. This provides a foundation of physician familiarity and trust.
• Sustained-Release Technology: The "SR" designation indicates a specific drug delivery system designed to release morphine gradually over time. This offers:
  • Improved patient compliance due to fewer daily administrations.
  • More stable plasma concentrations, potentially leading to more consistent pain control and reduced peak-and-trough effects.
  • Reduced risk of breakthrough pain compared to immediate-release products, although this is a complex clinical parameter.
• Cost-Effectiveness (Generic Status): As a product from Sandoz, a major generic pharmaceutical manufacturer, Oramorph SR is likely to be priced competitively. This is a critical factor in a market segment heavily influenced by formulary decisions and reimbursement policies.
• Specific Indication: While broadly for pain, its utility is concentrated in conditions requiring continuous opioid analgesia.

Who are the main competitors to Oramorph SR?

Competitors can be categorized by API, formulation, and therapeutic class.

Direct Competitors (Sustained-Release Opioid Analgesics):

• Morphine Sulfate SR Formulations: Numerous generic manufacturers offer sustained-release morphine sulfate tablets or capsules. Examples include products marketed by Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma. These products directly compete on price and availability.
• Other Opioid APIs in SR Formulations:
  • Oxycodone Controlled-Release (e.g., OxyContin, generic versions): A widely prescribed alternative, offering similar pain relief profiles but with different pharmacological properties and abuse-deterrent formulations in some cases.
  • Hydromorphone Extended-Release (e.g., Exalgo, generic versions): Another potent opioid with extended-release options.
  • Fentanyl Transdermal Patches (e.g., Duragesic, generic versions): Used for continuous, long-term pain management, offering an alternative delivery route.
  • Tramadol Extended-Release (e.g., Ultram ER, generic versions): A Schedule IV controlled substance with a dual mechanism of action, generally considered less potent than Schedule II opioids.

Indirect Competitors (Non-Opioid and Other Pain Management Modalities):

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Prescription and over-the-counter NSAIDs (e.g., ibuprofen, naproxen, celecoxib) are used for mild to moderate pain and inflammation.
• Acetaminophen (Paracetamol): Widely used for mild to moderate pain and fever.
• Adjuvant Analgesics: Medications like gabapentinoids (gabapentin, pregabalin), tricyclic antidepressants (TCAs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) are used for neuropathic pain and other chronic pain conditions.
• Topical Analgesics: Creams, gels, and patches containing lidocaine, capsaicin, or NSAIDs.
• Non-Pharmacological Therapies: Physical therapy, occupational therapy, acupuncture, cognitive behavioral therapy (CBT), spinal cord stimulation, and other interventional pain management techniques.

Patent and Regulatory Landscape

What is the patent status of Oramorph SR?

As Oramorph SR is a generic product (Sandoz), its active pharmaceutical ingredient, morphine sulfate, is off-patent. The original patents for the sustained-release formulation technology likely expired many years ago. Generic manufacturers like Sandoz enter the market after the expiry of relevant composition-of-matter and formulation patents.

• Generic Status: Oramorph SR is a generic version of existing sustained-release morphine sulfate products. Sandoz's ability to market Oramorph SR is contingent on demonstrating bioequivalence to the reference listed drug (RLD) and meeting all regulatory requirements for generic drug approval.
• Exclusivity: Any market exclusivity Sandoz might possess would be based on regulatory exclusivities granted by the FDA (e.g., 180-day exclusivity for first-to-file generics if applicable, though this is less common for established generics) or unique marketing agreements. However, the core patent protection for morphine and its basic sustained-release formulations has long since lapsed.

What are the key regulatory considerations for Oramorph SR?

The regulatory landscape for opioid analgesics is exceptionally stringent and subject to ongoing evolution.

• Controlled Substance Classification: Morphine sulfate is a Schedule II controlled substance under the U.S. Controlled Substances Act (CSA). This classification imposes strict regulations on manufacturing quotas, security, record-keeping, prescribing, dispensing, and distribution.
  • DEA Regulations: Manufacturers and distributors must adhere to DEA regulations regarding quotas, inventory control, and diversion prevention.
  • Prescription Requirements: Prescriptions for Schedule II drugs have specific requirements, including limitations on refills and electronic prescribing mandates in some jurisdictions.
• FDA Approval Process: Generic approval requires submission of an Abbreviated New Drug Application (ANDA) demonstrating:
  • Bioequivalence: Oramorph SR must be bioequivalent to the RLD, meaning it delivers the same amount of drug to the bloodstream over the same period.
  • Manufacturing Standards: Compliance with Current Good Manufacturing Practices (cGMP) is mandatory.
  • Labeling: Generic labeling must be comparable to the RLD, but may also include updates based on new safety information.
• Risk Evaluation and Mitigation Strategies (REMS): While Oramorph SR itself may not have a specific REMS program unique to its formulation, all Schedule II opioid analgesics are impacted by broader REMS requirements aimed at reducing opioid-related harm. This can include prescriber education and patient counseling requirements.
• State-Level Regulations: Individual states have their own prescription drug monitoring programs (PDMPs) and regulations concerning opioid prescribing limits, dispensing practices, and opioid treatment agreements.
• Post-Market Surveillance: The FDA and DEA actively monitor the safety and effectiveness of all approved drugs, with particular emphasis on controlled substances. Adverse event reporting and pharmacovigilance are critical.

Clinical Efficacy and Pharmacological Profile

What is the mechanism of action and expected clinical effect of Oramorph SR?

Oramorph SR contains morphine sulfate, a potent opioid agonist. Its mechanism of action is as follows:

• Mechanism of Action: Morphine acts primarily on mu-opioid receptors in the central nervous system (CNS) and the gastrointestinal tract.
  • Analgesia: Binding to mu-receptors in the brain and spinal cord modulates the perception of pain by inhibiting nociceptive pathways. It also affects descending pain control pathways.
  • Other Effects: Morphine also interacts with kappa and delta opioid receptors to a lesser extent, contributing to its broad pharmacological profile, including effects on mood, respiration, and gastrointestinal motility.
• Sustained-Release Formulation Effect: The SR formulation is designed to release morphine sulfate gradually over an extended period (typically 12 or 24 hours, depending on the specific product's design). This leads to:
  • Stable Plasma Concentrations: Aims for smoother pharmacokinetic profiles, avoiding the sharp peaks and troughs associated with immediate-release formulations.
  • Reduced Dosing Frequency: Allows for less frequent administration (e.g., twice daily) compared to immediate-release morphine.
  • Consistent Pain Relief: The goal is to provide continuous pain control, minimizing breakthrough pain episodes.
• Clinical Effect: Oramorph SR is indicated for the management of moderate to severe pain requiring continuous, around-the-clock opioid analgesia.
  • Efficacy: When dosed appropriately, it is expected to provide effective pain relief for conditions such as chronic cancer pain, severe osteoarthritis, or post-operative pain that requires prolonged management.
  • Limitations: Efficacy is dose-dependent and can be influenced by individual patient factors, including pain severity, genetics, tolerance, and concurrent medications. It is not intended for prn (as needed) pain relief.

What are the key adverse events associated with Oramorph SR?

As a Schedule II opioid, Oramorph SR carries significant risks and a well-documented profile of adverse events. These are consistent with morphine sulfate and other mu-opioid receptor agonists.

Common Adverse Events:

• Gastrointestinal: Nausea, vomiting, constipation (very common and often requires prophylactic treatment), dry mouth.
• Central Nervous System (CNS): Drowsiness, sedation, dizziness, lightheadedness, confusion, somnolence.
• Respiratory: Respiratory depression (dose-dependent, potentially life-threatening).
• Other: Pruritus (itching), urinary retention, headache, weakness.

Serious Adverse Events:

• Respiratory Depression: The most significant risk, potentially leading to hypoxia, respiratory arrest, and death, especially with dose escalation or co-administration with other CNS depressants.
• Opioid-Induced Hyperalgesia (OIH): Paradoxical increase in pain sensitivity with prolonged opioid exposure.
• Hypotension: Can occur, particularly with rapid dose titration or in patients with volume depletion.
• Serotonin Syndrome: Rare but serious, particularly when co-administered with serotonergic agents.
• Adrenal Insufficiency: Can occur with chronic use.
• Neonatal Opioid Withdrawal Syndrome (NOWS): If used during pregnancy.
• Abuse, Addiction, and Diversion: Significant risks associated with all Schedule II opioids.

Risk Management:

• Titration: Careful dose titration is essential to find the lowest effective dose.
• Monitoring: Regular assessment for efficacy and adverse events, including respiratory rate, level of consciousness, and pain control.
• Patient Education: Informing patients about potential side effects, safe storage, and risks of misuse.
• Co-administration Precautions: Avoiding concurrent use with other CNS depressants (e.g., benzodiazepines, alcohol, other sedatives) unless no alternative exists, and then with extreme caution.

Business and Financial Considerations

What is the business model for Sandoz with Oramorph SR?

Sandoz operates a generic pharmaceutical business model. For Oramorph SR, this entails:

• Manufacturing and Supply: Producing Oramorph SR in compliance with cGMP standards and ensuring a reliable supply chain. This includes sourcing API, manufacturing the finished dosage form, and distributing it to wholesalers and pharmacies.
• Cost Leadership: Competing primarily on price. Sandoz leverages its scale, efficient manufacturing processes, and established supplier relationships to produce generics at a lower cost than the innovator product.
• Market Access: Securing formulary placement with payers (insurance companies, government programs) and inclusion on hospital formularies. This often involves competitive bidding and demonstrating cost-effectiveness.
• Sales and Marketing: Targeting healthcare professionals (physicians, pain specialists, anesthesiologists) and pharmacies. Marketing efforts are typically focused on product availability, reliability, and competitive pricing, rather than extensive promotional campaigns seen with innovative drugs.
• Regulatory Compliance: Navigating the complex and evolving regulatory environment for controlled substances and generic drugs.

What are the key revenue drivers and cost factors for Oramorph SR?

Revenue Drivers:

• Market Share: The volume of Oramorph SR dispensed is the primary driver of revenue. This is influenced by its availability, physician prescribing patterns, payer coverage, and competitive pricing.
• Pricing: While generic prices are significantly lower than innovator prices, the average selling price (ASP) of Oramorph SR impacts revenue. Price erosion due to ongoing generic competition is a common characteristic of this market.
• Breadth of Distribution: Ensuring widespread availability across different geographic regions and healthcare systems.

Cost Factors:

• API Sourcing: The cost of morphine sulfate API is a significant input cost.
• Manufacturing and Production: cGMP compliance, quality control, and the physical production of tablets/capsules.
• Regulatory Compliance: Costs associated with DEA quotas, security measures, FDA filings, and ongoing pharmacovigilance.
• Distribution and Logistics: Warehousing, transportation, and supply chain management, particularly for controlled substances.
• Sales and Marketing: While less intensive than for novel drugs, costs for detailing, medical education, and market access are incurred.
• Research and Development (for generics): While not R&D for a new drug, costs are associated with bioequivalence studies, ANDA development, and process optimization.
• Litigation and Legal Costs: Potential costs related to patent challenges (though less relevant for a generic), regulatory actions, or product liability.

What are the risks associated with investing in Oramorph SR or similar generic opioid products?

Investing in generic opioid products like Oramorph SR carries specific risks:

• Regulatory Risk:
  • Increased Scrutiny and Restrictions: Potential for further regulatory restrictions on opioid prescribing, manufacturing, or distribution due to the ongoing opioid crisis. This can lead to reduced demand and higher compliance costs.
  • DEA Quota Changes: Fluctuations in DEA manufacturing quotas can impact supply and production volumes.
  • Labeling Changes: New safety warnings or contraindications could impact market acceptance or necessitate reformulation.
• Market Risk:
  • Price Erosion: Intense competition among generic manufacturers leads to significant price declines over time.
  • Shifting Treatment Paradigms: A continued movement towards non-opioid pain management and alternative therapies could reduce the overall demand for opioid analgesics.
  • Payor Restrictions: Payer policies may increasingly favor non-opioids or limit access to certain opioid formulations.
• Litigation Risk:
  • Product Liability Lawsuits: While less common for generics than for innovators, manufacturers can still face litigation related to product safety, marketing, or manufacturing defects.
  • Opioid Litigation: The broader landscape of opioid litigation against pharmaceutical companies could indirectly impact generic manufacturers through reputational damage, increased insurance premiums, or regulatory precedents.
• Operational Risk:
  • Supply Chain Disruptions: Sourcing API and maintaining the complex logistics for controlled substances can be vulnerable to disruptions.
  • Manufacturing Quality Issues: Non-compliance with cGMP can lead to product recalls, manufacturing halts, and regulatory sanctions.
• Reputational Risk: Association with the opioid class of drugs can carry a negative public perception, even for generic manufacturers.

Key Takeaways

• Oramorph SR is a generic sustained-release oral formulation of morphine sulfate, operating in a mature and highly competitive market segment.
• Its competitive advantage lies in its established API, a proven sustained-release delivery system, and price competitiveness as a generic product.
• The drug is subject to stringent regulatory oversight due to morphine's Schedule II controlled substance classification, impacting manufacturing, distribution, and prescribing.
• Key risks for investors include ongoing price erosion, regulatory tightening related to the opioid crisis, shifts towards non-opioid alternatives, and potential litigation.
• Revenue is driven by market share and dispensing volumes, while costs are significantly influenced by API sourcing, manufacturing, and strict regulatory compliance.

Frequently Asked Questions

1. What is the primary indication for Oramorph SR? Oramorph SR is indicated for the management of moderate to severe pain requiring continuous, around-the-clock opioid analgesia.

2. How does Oramorph SR differ from immediate-release morphine? Oramorph SR is designed to release morphine sulfate gradually over an extended period, aiming for smoother plasma concentrations and reduced dosing frequency compared to immediate-release formulations.

3. What are the most significant risks associated with Oramorph SR? The most significant risks include respiratory depression (a potentially life-threatening side effect), addiction, abuse, diversion, and regulatory scrutiny due to its Schedule II controlled substance classification.

4. Is Oramorph SR still under patent protection? No, as a generic product, the active pharmaceutical ingredient (morphine sulfate) and its basic sustained-release formulation technology are off-patent. Sandoz's ability to market it relies on demonstrating bioequivalence and regulatory approval.

5. What is the impact of the opioid crisis on the market for Oramorph SR? The opioid crisis has led to increased regulatory scrutiny, stricter prescribing guidelines, and a societal push towards non-opioid pain management alternatives, all of which can negatively impact the demand and market access for opioid analgesics, including Oramorph SR.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Controlled Substances Act (CSA). Retrieved from [FDA website - specific page on CSA not directly linked here but general reference]

[2] U.S. Drug Enforcement Administration. (n.d.). Schedules of Controlled Substances. Retrieved from [DEA website - specific page on schedules not directly linked here but general reference]

[3] Sandoz. (n.d.). Product Information Leaflet/Labeling. (Specific product details would be retrieved from the FDA's Drugs@FDA database or the company's official product information, not directly cited from a general company page).